Compare Nakanishi, Inc. with Similar Stocks
Dashboard
1
High Management Efficiency with a high ROE of 10.82%
2
Company has very low debt and has enough cash to service the debt requirements
3
With a growth in Net Sales of 0.28%, the company declared Very Positive results in Mar 26
4
With ROE of 9.98%, it has a risky valuation with a 2.28 Price to Book Value
5
Majority shareholders : FIIs
6
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
7
Underperformed the market in the last 1 year
Stock DNA
Pharmaceuticals & Biotechnology
JPY 281,266 Million (Small Cap)
23.00
NA
0.00%
-0.24
12.82%
2.42
Revenue and Profits:
Net Sales:
22,489 Million
(Quarterly Results - Mar 2026)
Net Profit:
3,980 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.81%
0%
7.81%
6 Months
49.39%
0%
49.39%
1 Year
58.36%
0%
58.36%
2 Years
18.09%
0%
18.09%
3 Years
-8.02%
0%
-8.02%
4 Years
20.42%
0%
20.42%
5 Years
21.98%
0%
21.98%
Nakanishi, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
19.69%
EBIT Growth (5y)
10.53%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.54
Tax Ratio
49.70%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
23.45%
ROE (avg)
10.82%
Valuation key factors
Factor
Value
P/E Ratio
23
Industry P/E
Price to Book Value
2.28
EV to EBIT
15.94
EV to EBITDA
11.29
EV to Capital Employed
2.88
EV to Sales
2.77
PEG Ratio
1.25
Dividend Yield
NA
ROCE (Latest)
18.05%
ROE (Latest)
9.98%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
No Trend
OBV
No Trend
Bullish
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - QoQ
Mar'26
Dec'25
Change(%)
Net Sales
22,488.70
22,426.40
0.28%
Operating Profit (PBDIT) excl Other Income
5,876.20
5,113.10
14.92%
Interest
71.20
73.60
-3.26%
Exceptional Items
0.00
-13,766.90
100.00%
Consolidate Net Profit
3,980.30
-8,579.30
146.39%
Operating Profit Margin (Excl OI)
207.90%
158.20%
4.97%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2026 is 0.28% vs 14.64% in Dec 2025
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2026 is 146.39% vs -421.24% in Dec 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
81,179.10
77,041.40
5.37%
Operating Profit (PBDIT) excl Other Income
19,899.40
20,460.40
-2.74%
Interest
199.20
67.30
195.99%
Exceptional Items
-13,627.40
-3,464.50
-293.34%
Consolidate Net Profit
-2,398.20
8,578.80
-127.95%
Operating Profit Margin (Excl OI)
173.60%
189.50%
-1.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.37% vs 29.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -127.95% vs -62.44% in Dec 2024
About Nakanishi, Inc. 
Nakanishi, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






